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ABSTRACT
Introduction The aim of this study is to investigate 
the effects of time- restricted eating (TRE) on change 
in body weight and describe changes in behaviour 
and metabolism in individuals at high risk of type 2 
diabetes.
Methods and analysis The REStricted Eating Time 
(RESET) study is a randomised controlled parallel- 
group open- label trial. 100 women and men with (1) 
overweight (body mass index (BMI)≥25 kg/m2) and 
prediabetes (glycated haemoglobin 39–47 mmol/mol); 
or (2) obesity (BMI≥30 kg/m2) will be randomised to 
a control group (habitual living) or TRE (self- selected 
10- hours eating window within the period from 
06:00 to 20:00 in a 1:1 ratio. Testing is scheduled 
at baseline and after 6 weeks (mid- intervention), 3 
months (post- intervention) and 6 months (follow- up). 
The primary outcome is change in body weight after 3 
months of intervention. Secondary outcomes include 
changes in body composition; measures of glucose 
metabolism including glycaemic variability, hormones 
and metabolites; subjective and metabolic markers of 
appetite, food preferences and reward; dietary intake; 
physical activity, sleep, chronotype; gastric emptying, 
gastrointestinal transit time and motility; respiratory 
and glycolytic capacities; the plasma proteome and 
metabolome; blood pressure, resting heart rate and 
heart rate variability; and resting energy expenditure 
and substrate oxidation. Motivation and feasibility 
will be examined based on interviews at baseline 
and after 3 months. After the 3- month intervention, a 
3- month follow- up period and subsequent testing are 
scheduled to assess maintenance and longer- term 
effects.
Ethics and dissemination The study has been approved 
by the Ethics Committee of the Capital Region of Denmark 
(H-18059188) and the Danish Data Protection Agency. 
Strengths and limitations of this study
 ► The study includes state- of- the- art and novel tech-
nologies to assess the effects of the intervention on 
food preferences and reward, the gastrointestinal 
tract, respiratory and glycolytic capacities, as well 
as proteomics and metabolomics.
 ► The interdisciplinary nature of the study and as-
sessment of feasibility and sustainability using 
qualitative methods allow an understanding of the 
participants’ experiences and potential barriers and 
strategies for integration and maintenance of time- 
restricted eating in everyday life.
 ► The duration of the trial does not allow for the inves-
tigation of long- term effects and hard endpoints, but 
the follow- up visit allows for the evaluation of main-
tenance 3 months after the end of the intervention.
 ► Except for reminders regarding reporting of daily 
eating windows, no support to comply with the pre-
scribed intervention is provided to the participants 
during the trial; adherence is therefore entirely de-
pendent on the motivation and self- determination of 
the participants.
 ► While the broadness of the inclusion criteria allows 
for the recruitment of a study population more alike 
to the general population at risk for type 2 diabetes 
and cardiovascular disease, it at the same time in-
creases the risk for heterogeneity in the effects of 
some of the secondary outcomes.
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The study will be conducted in accordance with the Declaration of 
Helsinki. Results from the study will address whether TRE is effective and 
feasible in improving health outcomes in individuals at risk of lifestyle- 
related diseases and can potentially inform the design of feasible health 
recommendations.
Trial registration number NCT03854656.
INTRODUCTION
Overweight and pre- diabetes increase the risk of devel-
oping type 2 diabetes and cardiovascular disease.1–3 
Weight loss is associated with improved glycaemic control 
and cardiometabolic health among individuals with pre- 
diabetes and type 2 diabetes4 5; therefore, the develop-
ment of effective, feasible and sustainable weight loss 
strategies is essential. Current prevention and treatment 
of obesity and type 2 diabetes include energy- restricted 
diets and increased levels of physical activity.6 However, 
adherence and maintenance to such strategies are diffi-
cult,7 8 underscoring an unmet need for more acceptable 
and feasible regimens.
Circadian rhythms are ~24- hour rhythms of behaviour 
and metabolism that are closely related to the daily light/
dark cycle and sleep–wake patterns.9 10 The timing of 
food intake may affect the circadian rhythms of meta-
bolic organs.9 Factors including the 24- hour availability of 
energy- dense foods and different eating and sleep patterns 
during weekdays and weekends (ie, ‘social jetlag’) may 
lead to an irregular feeding–fasting rhythm.11 12 Obser-
vational studies suggest that irregular eating patterns 
and late- night food consumption are associated with 
increased cardiometabolic risk.13 Experimental studies in 
rodents and humans have shown that circadian misalign-
ment of food intake and sleep may have adverse effects on 
energy balance, glucose metabolism and appetite regu-
lation,14–17 suggesting a great therapeutic potential of 
aligning food intake to circadian rhythms of metabolism. 
Studies in rodents and flies suggest that time- restricted 
feeding is associated with improvements in metabolic 
health including improved glucose and lipid metabo-
lism and reductions in adiposity and systemic inflamma-
tion.9 18 However, there is a lack of randomised controlled 
trials (RCTs) investigating the effects of timing of food 
intake on human behaviour and metabolism.
Recent cross- over intervention studies in humans have 
investigated the short- term (4 days–5 weeks) effects of 
time- restricted eating (TRE) under well- controlled condi-
tions. Among men at high risk of type 2 diabetes, ‘early 
TRE’ (eating window: 6–9 hours/day, between 08:00 and 
17:00) improved glucose metabolism19–21 and reduced 
appetite.19 22 A few small pilot intervention studies 
(n=8–23) have investigated the effects of 10–16 weeks 
of TRE (eating window: ~8–12 hours/day) in individuals 
with overweight and obesity and reported reductions in 
energy intake and body weight11 23 24 and adiposity.24 25 
Furthermore, in one of the studies, in which a clinically 
relevant weight loss (3.9%) was observed, the partici-
pants felt more energetic and reported less hunger and 
improved sleep quality; however, no control group was 
included.11 In the same study, maintenance was assessed 
at a 1- year follow- up. Importantly, on completion of the 
16- week intervention, all eight participants in the same 
study were interested in continuing the regimen, and they 
maintained weight loss at follow- up (3.4%),11 suggesting 
that TRE may be feasible, acceptable and sustainable. 
Additionally, the long fasting period during ‘early TRE’ 
seems to be well tolerated19; however, challenges asso-
ciated with social events including drinking and eating 
may exist.25 Nevertheless, an in- depth investigation of the 
feasibility and sustainability of TRE is needed to under-
stand motivation and potential barriers for integration 
and maintenance in everyday life. In this study, the effects 
and feasibility of TRE in individuals at high risk of type 
2 diabetes will be assessed using an interdisciplinary 
approach including state- of- the- art and novel quantitative 
and qualitative methods.
OBJECTIVES
The primary objective of the REStricted Eating Time 
(RESET) study is to investigate the effects of 3 months of 
TRE (10 hours/day) on change in body weight in individ-
uals at high risk of type 2 diabetes. Secondary objectives 
are to describe changes in body weight and composition, 
metabolism and behaviour and to assess aspects related to 
motivation, feasibility and maintenance during the 3- month 
intervention and after additional 3 months of follow- up.
HYPOTHESES
We hypothesise that 3 months of TRE will induce a clin-
ically relevant weight loss in individuals with overweight 
and obesity at high risk of type 2 diabetes (ie, TRE supe-
rior to control). Furthermore, we expect that weight loss 
is maintained in the TRE group at the 3- month follow- up 
visit (ie, TRE superior to control).
METHODS AND ANALYSIS
Study design
The study is a single- centre, parallel- group, randomised, 
controlled, superiority, open- label trial (figure 1). A total 
of 100 individuals will be randomised to 3 months of TRE 
or habitual living (control) in a 1:1 ratio. Habitual living 
was chosen as the comparator to evaluate the effects of 
TRE when included in everyday routines. Randomisation 
is performed after completion of screening and baseline 
testing (visit 1 (V1)). The primary outcome is assessed 
after 3 months of intervention (V3). At baseline, mid- 
intervention (after 6 weeks; V2) and after the intervention 
(3 months; V3), outcomes are assessed during test days 
and free- living measurements during the week following 
the test days. After the 3- month intervention, a 3- month 
follow- up period and subsequent testing (V4) are sched-
uled to assess maintenance and longer- term effects. The 
trial will be performed at Steno Diabetes Center Copen-
hagen and will be reported according to the Consolidated 
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Standards of Reporting Trials (CONSORT).26 The study 
protocol follows the Standard Protocol Items: Recom-
mendations for Interventional Trials statement.27 A copy 
of the WHO Trial Registration Data Set is supplied in the 
online supplementary table 1.
Participants
Women and men, 30–70 years of age, with (a) over-
weight (body mass index (BMI)≥25 kg/m2) with concom-
itant pre- diabetes as defined by glycated haemoglobin 
(HbA1c) 39–47 mmol/mol6 or (b) obesity (BMI≥30 kg/
m2), who are eligible according to the inclusion and 
exclusion criteria (box 1) will be included.
Eligibility criteria
Inclusion and exclusion criteria are listed in box 1. We 
include high- risk individuals aged 30–70 years because 
our focus is on preventing diabetes at an early stage. 
Individuals with overweight and pre- diabetes and obesity 
with/without pre- diabetes are included to target indi-
viduals at high risk of type 2 diabetes. The rationale of 
choosing 70 years as the upper limit is that the potential 
for prevention is limited in older individuals. To prevent 
sources of circadian irregularity during the intervention, 
shift workers and individuals with a partner engaged in 
shift work affecting the circadian rhythm of the partici-
pant are not eligible for participation.
Recruitment and screening
Participants are recruited through advertisements on 
different publicly available platforms (newspapers, 
webpages, pharmacies and so on). A pre- screening is 
performed as a telephone interview focusing on the 
participant’s age, BMI and habitual eating window to 
reduce the number of screen failures. Participants who 
are eligible based on the pre- screening receive written 
information about the study and are scheduled for a 
screening visit (V0). At the screening visit, participants 
provide oral and written informed consent to medical 
staff, and a health examination including medical history 
and assessment of inclusion and exclusion criteria is 
performed (box 1). After the screening, eligible partic-
ipants will be scheduled for four visits (V1–V4, figure 1). 
Baseline testing (V1) takes place as soon as possible and 
within 6 weeks from the screening visit (V0). The first 
participant signed consent on 25 February 2019, and 
participants are recruited continuously.
Outcomes
Primary outcome
The primary outcome is mean change in body weight 
(kg) from baseline (V1) to the end of intervention (after 
3 months, V3). Change in body weight was chosen as the 
primary outcome for several reasons. First, weight loss is 
associated with a reduction in all- cause mortality in indi-
viduals with obesity28 and with improvement in glycaemic 
control in individuals with overweight and obesity.4 
Second, according to the American Diabetes Associa-
tion, weight loss is recommended for all individuals with 
pre- diabetes.6 Third, body weight is easy to measure with 
high precision and available in most clinical studies that 
enable determination of sample size and comparison 
across studies.
Secondary exploratory outcomes
The secondary exploratory outcomes include a variety 
of metabolic and behavioural outcomes potentially asso-
ciated with the intervention. These include changes 
in body composition, hormones involved in glucose 
metabolism and appetite regulation (eg, pancreatic and 
gastrointestinal hormones), metabolites and glycaemic 
variability; subjective appetite, food preferences and 
reward, and eating behaviour; gastric emptying, gastro-
intestinal motility and transit time; gut microbiome; 
physical activity, dietary intake and sleep; inflammatory 
markers; respiratory and glycolytic capacities; the plasma 
proteome and metabolome; blood pressure, resting heart 
rate and heart rate variability; and resting energy expen-
diture and substrate oxidation (table 1). We describe 
changes from baseline to mid- intervention (after 6 weeks; 
V2), post- intervention (after 3 months; V3) and follow- up 
testing (after 6 months; V4).
Study visits and free-living assessment periods
The study includes identical test days and free- living assess-
ment periods at baseline (before randomisation, V1) and 
postintervention (V3). The test day at V3 is scheduled after 
12 weeks intervention; however, participants are instructed 
Figure 1 Study design.
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to follow their group allocation during the subsequent 
1- week free- living assessment period (ie, 13th week of 
the intervention). Mid- intervention testing after 6 weeks 
(V2) includes a short test day and a subsequent free- living 
assessment period during which participants follow their 
group allocation. After the 13- week follow- up period (26 
weeks from baseline), a short test day (V4) is scheduled to 
Box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Age: ≥30 to ≤70 years.
 ► Body mass index ≥30 kg/m2 or body mass index ≥25 kg/m2 in com-
bination with pre- diabetes (HbA1c ≥39 to <48 mmol/mol).
 ► Habitual eating/drinking window ≥12 hours (including foods/snacks 
and energy- containing beverages, eg, soft drinks (except water)) 
and an eating/drinking window of ≥14 hours minimum 1 day/week.
Exclusion criteria
 ► Daily smoking.
 ► For women: pregnancy, planned pregnancy (within the study period) 
or lactating.
 ► Frequent travels over time zones (more than one return trip/trav-
el over times zones (˃1 hour time difference) during the 13- week 
intervention).
 ► Shift work or partner engaged in shift work (if it affects the person’s 
sleep and eating pattern).
 ► Unable to understand the informed consent and the study 
procedures.
 ► Self- reported history of an eating disorder during the past 3 years.
 ► Self- reported weight change (>5 kg) within 3 months prior to 
inclusion.
 ► Known diabetes or diabetes detected at screening (HbA1c ≥48 
mmol/mol).
 ► Uncontrolled medical issues including but not limited to cardiovas-
cular, pulmonary, rheumatological, haematological, oncological, in-
fectious, gastrointestinal or psychiatric disease; endocrine disease; 
immunosuppression.
 ► Current treatment with medication or medical devices that signifi-
cantly affect glucose metabolism, appetite or energy balance.
 ► Current treatment with antidepressants.
 ► Bariatric surgery.
 ► Implanted or portable electromechanical medical device such as a 
cardiac pacemaker, defibrillator or infusion pump.
 ► Coeliac disease, Crohn’s disease, ulcerative colitis or proctitis.
 ► Alcohol/drug abuse or in treatment with disulfiram at time of 
inclusion.
 ► Concomitant participation in other intervention studies.
 ► Not able to eat ≥85% of the test meal because of, eg, allergy.
Specific exclusion criteria for participants receiving SmartPill
 ► Gastrointestinal symptoms or diseases such as regular (weekly) ab-
dominal pain, dysphagia, gastric bezoars, strictures, fistulas, bowel 
obstructions or diverticulitis.
 ► Current treatment with medication or medical devices that signifi-
cantly affect gastrointestinal motility or transit time (prokinetics, 
antidiarrhoeals, laxatives or opioids).
 ► Gastrointestinal surgery within 3 months before inclusion.
Other criteria for withdrawal and exclusion after inclusion
 ► Participant’s withdrawal of the informed consent.
 ► Pregnancy or other safety concerns—judged by the investigator.
HbA1c, glycated haemoglobin.
Table 1 Overview of study visits
Visit V0 V1 V2 V3 V4
Time, weeks from start of 
intervention
−7* −1 6 12 26
Participant information           
  Informed consent X         
  Medical history (individual 
and family)
X         
  Inclusion and exclusion 
criteria
X         
  Pregnancy test (fertile 
women only)
  X X X X
Efficacy outcomes           
  HbA1c X X X X X
  Body weight X X X X X
  Waist and hip circumference   X X X X
  Body composition (DXA 
scanning)
  X X X X
  Blood pressure and resting 
heart rate
X X X X X
  Stool sample   X   X   
  Fasting blood samples   X X X X
  Postprandial blood samples   X   X   
  Indirect calorimetry   X   X   
  Heart rate variability (Vagus)   X   X   
  Mixed meal test with 
SmartPill
  X   X   
  Event registration related to 
SmartPill
  X   X   
  Physical activity and sleep 
measurement
  X X X   
  Food records   X X X   
  Continuous glucose 
monitoring
  X X X   
  Fasting food reward and 
biometric measurements
  X X X X
  Postprandial food 
reward and biometric 
measurements
  X   X   
Questionnaires           
  Sociodemographic 
characteristics
  X       
  Health and well- being   X X X X
  Physical activity   X X X X
  Fasting appetite sensations   X X X X
  Postprandial appetite 
sensations
  X   X   
  Gastrointestinal symptoms   X X X X
  Autonomic symptoms   X       
  Pain   X       
  Sleep quality and sleepiness   X X X X
Continued
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assess the maintenance of potential intervention effects. If 
possible, all 4 test days are scheduled on similar weekdays 
and at the same time in the morning. An overview of the 
study visits is presented in table 1.
Test days
All clinical examinations are conducted at Steno Diabetes 
Center Copenhagen. Participants arrive in the morning at 
∼08:00 am after a ∼12 hours overnight fast. All participants 
are instructed to have a last meal between 19:00 and 20:00 
the day prior to the test days to minimise the potential 
acute effects of varying fasting duration on the outcomes 
of interest.29 Furthermore, no alcohol consumption or 
strenuous physical activity is allowed 48 hours prior to 
testing. The participants are instructed to avoid physically 
demanding transportation to the research facility.
Anthropometry
Height is measured using a stadiometer (SECA, 
Vogel&Halke, Hamburg, Germany) and body weight 
is measured using a digital scale (Tanita BWB- 620A, 
Amsterdam, The Netherlands) while participants are 
wearing only light clothes/underwear. Waist circumfer-
ence is measured at the midpoint between the lowest 
point of the lowest rib and the highest point of the iliac 
crest. Hip circumference is measured at the point of the 
greater femoral trochanter. An average of two repeated 
measurements of hip and waist circumference is used. In 
the case of ˃3 cm difference between the two measure-
ments, a third measurement is conducted, and the average 
of the two closest measurements is used. Body compo-
sition (fat mass and fat- free mass) is measured using 
whole- body dual- energy X- ray absorptiometry (Discovery, 
Hologic, Bedford, Massachusetts, USA). A urine sample is 
collected, and a pregnancy test is performed for all fertile 
women <60 years before the scan.
Blood pressure and resting heart rate
Blood pressure (mmHg) and resting heart rate (beats 
per minute) are measured three times with 2 min inter-
vals using a digital blood pressure monitor (UA-852, A&D 
Instruments, Abingdon, UK) after a minimum of 10 min 
rest, and the average of the two lowest values of three 
consecutive measurements are used to avoid falsely high 
blood pressure caused by an unfamiliar and potentially 
stressful environment.
Heart rate variability
Heart rate variability and cardiovascular reflex are 
measured by electrocardiography using a handheld 
device (Vagus, Medicus Engineering, Aarhus, Denmark) 
during four consecutive tests: (1) resting heart rate is 
measured while the participant is in the supine position 
holding the device; (2) heart rate response to standing 
up from the supine position; (3) heart rate response to 
inhalation and exhalation is measured in the seated posi-
tion; (4) heart rate response to increased intrathoracic 
pressure (Valsalva manoeuvre).
Resting energy expenditure and substrate oxidation
Resting energy expenditure and substrate oxidation are 
measured for 30 min using indirect calorimetry and a 
ventilated hood (Vyntus CPX, CareFusion, Hoechberg, 
Germany) with the participant resting in the supine posi-
tion in a quiet room. Energy expenditure30 and substrate 
oxidation31 are calculated based on respiratory gas 
exchange, that is, carbon dioxide production and oxygen 
consumption.
Blood samples
Venous blood samples are collected in the fasting state 
at all 4 test days (V1–V4) and postprandially during a 
mixed meal test at V1 and V3 at time points 15, 30, 45, 
60, 90, 120, 180 and 240 min via a catheter in an antecu-
bital vein. Analyses include assessment of HbA1c, circu-
lating levels of glucose and lipids, inflammatory markers 
and hormones involved in the regulation of appetite 
and metabolism (eg, insulin, glucagon, glucagon- like 
peptide-1, glucose- dependent insulinotropic polypeptide, 
peptide YY and acylated ghrelin). Furthermore, metabo-
lomics and proteomics will be applied, and assessment of 
circulating proteins and metabolites that correlate with 
low- grade inflammation and markers of lipid metabolism 
will be captured using mass- spectrometry- driven anal-
yses of the plasma proteome and metabolome.32 33 Gene 
expression of proinflammatory and anti- inflammatory 
proteins including cytokines and chemokines and genes 
involved in the energy metabolism of isolated peripheral 
blood mononuclear cells will be measured by real- time 
PCR. Cellular bioenergetic activity (mitochondrial respi-
ration and glycolysis) of isolated peripheral blood mono-
nuclear cells will be determined using a Seahorse XFe24 
Analyzer.34 The seahorse technology measures real- time 
oxygen consumption rate as an indicator of mitochon-
drial activity and extracellular acidification rate as an 
Visit V0 V1 V2 V3 V4
  Chronotype   X X X X
  Night eating   X X X X
  Eating behaviour and 
control over eating
  X X X X
Interviews           
  Interview†   X       
  Interview (participants in the 
TRE group)‡
      X X
*Max 6 weeks before baseline testing (V1).
†Interview regarding motivation for participation.
‡Interview regarding feasibility and maintenance.
DXA, dual- energy X- ray absorptiometry; HbA1c, glycated 
haemoglobin; TRE, time- restricted eating; V0, screening; 
V1, baseline testing; V2, mid- intervention testing (after 6 
weeks); V3, post- intervention testing (after 3 months); V4, 
follow- up testing (after 6 months).
Table 1 Continued
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indicator of glycolytic activity. Thus, these measurements 
will provide mechanistic knowledge of TRE- induced 
metabolic changes at the cellular level. Serum and plasma 
will be stored in a biobank for future analyses.
Meal test
At V1 and V3, after assessments in the fasting state, partic-
ipants are asked to consume a standard breakfast meal 
(300 g, 498 kcal, 49% of total energy (%E) carbohydrate, 
34 E% fat and 17 E% protein) consisting of bread roll, rye 
bread, cheese, yoghurt, muesli, butter, marmalade and 
150 mL water. For the following 4 hours after initiation of 
the meal, blood samples are collected and subjective appe-
tite is assessed using visual analogue scales35 at time points 
15, 30, 45, 60, 90, 120, 180 and 240 min.
Subjective appetite
Hunger, satiety, fullness, thirst, estimated prospective 
food consumption and desire for sweet, salt and fat, and 
potential nausea are rated by the participants using elec-
tronic visual analogue scales35 after the blood samples in 
the basal state at all 4 test days (V1–V4) and postprandi-
ally at V1 and V3.
Food preferences and food reward
At V1 and V3, components of food reward and biometric 
responses to standardised photographic images of foods 
will be assessed in the fasting state and 60 min after 
ingestion of the standardised breakfast meal to examine 
meal- induced changes in food reward and responses 
to food stimuli. At V2 and V4, only fasting measure-
ments of food reward and biometric responses will be 
performed. In a computerised questionnaire, different 
food reward outcomes (food choice, implicit wanting, 
explicit liking and explicit wanting) are measured using 
the Leeds Food Preference Questionnaire36–38 in combi-
nation with measures of autonomic nervous system 
activity including arousal estimated from galvanic skin 
response (Biopac MP160, Biopac Systems, Goleta, Cali-
fornia, USA), emotional response using facial expression 
analyses (AFFDEX algorithm, Affectiva, Massachusetts, 
USA), and motivated visual attention using eye tracking 
(Tobii X2-60, Tobiipro, Stockholm, Sweden). The Leeds 
Food Preference Questionnaire is integrated into a 
biometric software platform (iMotions A/S, Frederiks-
berg, Denmark) to enable the simultaneous collection 
of data on eye tracking, galvanic skin response and facial 
expressions.
Questionnaires
At V1–V4, participants fill in questionnaires regarding 
health and well- being, gastrointestinal and autonomic 
symptoms, eating behaviour, chronotype, sleep and 
physical activity (table 1). At V1, participants fill in a 
questionnaire regarding sociodemographic character-
istics including age, sex, ethnicity, education, occupa-
tion, civil status, children and personal and household 
income.
Interviews
Interviews will be conducted at V1, V3 and V4 to obtain 
insights into the participants’ experiences and perceptions 
of the intervention. This will provide an understanding of 
the feasibility and integration of the intervention into the 
everyday life of the participants as well as maintenance 
of the regimen. At V1, participants will be interviewed 
for ~25 min to examine their reasons and motivation for 
participation, their expectations towards the intervention 
and their everyday life activities and eating practices.
At V3 and V4, participants in the TRE group will be 
invited to individual semistructured interviews of ~45 min 
to explore the feasibility and maintenance of TRE in 
everyday life. If participants withdraw from the study, 
then they will be invited to individual interviews about 
their reasons for doing so and their experiences with the 
intervention. The interviews will draw on social practice 
theory39 and will be recorded and transcribed verbatim. 
Malterud’s systematic text condensation approach40 will 
be used to analyse the interview data.
Free-living assessment period
A 1- week free- living assessment period is scheduled after 
each of the test days at V1–V3 and includes the proce-
dures described further. Participants are instructed to 
follow group allocation during the assessment period at 
V2 and V3. After the 1- week free- living assessment period 
at V3, the participants will be instructed to live as they 
wish during the subsequent 3- month follow- up period.
Gastric emptying, gastrointestinal transit times and motility
At V1 and V3, participants will be instructed to ingest a 
wireless motility capsule (SmartPill, Medtronic, Minne-
sota, USA) immediately after ingesting the standardised 
breakfast meal with 150 mL water. The capsule measures 
pH, temperature and pressure through the gastrointes-
tinal tract until expulsion. From these data, regional 
transit time, pH profile and motility in different parts of 
the gastrointestinal tract can be estimated.41–43 Partici-
pants will be instructed to wear a SmartPill receiver unit 
within 0.25 m of their body for the following week or 
until the expulsion of the capsule. As this is an expen-
sive measurement, only the first ~60 participants will be 
offered the capsule.
Events related to the gastrointestinal tract
At V1 and V3, participants register all events related to 
the gastrointestinal tract (passing stool, eating, sleeping, 
and gastrointestinal symptoms such as nausea, vomiting, 
pain in the abdominal region, bloating and so on), until 
the expulsion of the SmartPill, using an ‘event button’ 
on the SmartPill receiver. Additionally, the participants 
register the time and type of each event in a diary.
Physical activity and sleep
Physical activity and sleep will be measured using accel-
erometry. Participants will be equipped with one acceler-
ometer on the thigh and one on the lower back for 1 week 
(Axivity AX3, Newcastle upon Tyne, UK). Concomitant 
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with wearing the accelerometers, participants will be 
asked to fill out a physical activity and sleep diary.
Continuous glucose monitoring
A 1- week continuous glucose monitoring (CGM) system 
(Ipro, Medtronic Denmark A/S, Copenhagen, Denmark) 
will be initiated at the test days at V1–V3. The CGM will be 
attached to the lower part of the abdomen in the morning 
at the test days. Participants will be instructed to measure 
blood glucose levels using a glucometer (Contour XT, 
Ascensia Diabetes Care Denmark ApS, Copenhagen, 
Denmark) four times a day during the measurement 
period for the calibration of the CGM (before breakfast, 
lunch, main evening meal and bedtime).
Dietary intake
During the week following V1, V2 and V3, participants 
will be asked to fill in a food record diary (pen and paper) 
for 3 days (day 1, 3 and 5 after the test day; 2 weekdays and 
1 weekend day). Participants will be instructed to register 
weight, time and content of all meals and beverages 
(except water). During the same week, participants will 
be asked to register their eating window (see the Assess-
ment of adherence section).
Participants will be instructed to send the CGM, Smart-
Pill receiver, accelerometers and diaries to the researchers 
after completion of each assessment period.
Gut microbiome
Participants will be provided with a kit for stool samples 
including storage equipment at V0 and V2. They will be 
instructed to collect and immediately freeze (−20°C) three 
samples from the same stool sample ≤72 hours before 
test days at V1 and V3. The participants will transport the 
samples to the laboratory in provided cooling bags and 
the samples will be stored at −80°C until analysis. Bacterial 
DNA and RNA will be purified from the stool samples. The 
microbial content, composition and function will be esti-
mated based on the sequencing of the microbiome.
Randomisation and intervention
After completing baseline testing, participants are 
randomly allocated to either the control group or the TRE 
group. Randomisation is performed in blocks varying in 
size, unknown to the researchers, to ensure an equal distri-
bution of participants in the two groups in case the study, 
for unexpected reasons, must be terminated before the 
inclusion of all participants. The randomisation list was 
generated by an external statistician and uploaded to the 
electronic data management system REDCap (V.8.10.18, 
Vanderbilt University, Tennessee, USA). When partici-
pants leave the research facilities on the test day at V1, 
they receive a sleeve with a combination lock that contains 
information about group allocation. On day 7, when all 
baseline assessments are completed, the participants are 
provided with the code for the lock by an investigator. 
This approach ensures that participants are blinded to 
the group allocation during the 7 day free- living assess-
ment period. Over the phone, the investigator provides 
a detailed description and introduction to the specific 
group allocation. For practical reasons, randomisation 
is open for participants and research staff. However, the 
outcome assessors (data analysts) will be blinded during 
the statistical analyses of all experimental outcomes.
Time-restricted eating
Participants allocated to the TRE group are instructed to 
consume all foods and beverages (except water) within a 
self- selected time window of 10 hours/day between 06:00 
and 20:00 for the 13- week intervention. Furthermore, the 
participants are instructed to keep the eating window stable 
during the entire week and advised to select a window which 
starts at least 2 hours after habitual wake- up time and stops 
3 hours before habitual bedtime if possible. Participants are 
advised to follow the Danish dietary recommendations.44 
No other dietary restrictions are prescribed.
Control
Participants allocated to habitual living are advised to 
follow the Danish dietary recommendations44 but are 
otherwise instructed to continue their habitual lifestyle 
during the 13- week intervention.
Assessment of adherence
All participants are asked to register time for initiating 
first and terminating the last eating/drinking episode 
(except water) every day from the test day at V1–V4. 
Every week during the 26- week period (intervention and 
follow- up), a link to an online form will be sent by email to 
the participants for them to register the time for eating/
drinking episodes for the previous week. In case partic-
ipants in the control group restrict their eating window 
to less than their habitual ≥12 hours/day or if the eating 
window of participants in the TRE group deviates from 
their self- selected 10 hours eating window ≥4 days during 
the first week, then the participant will be contacted per 
telephone to ensure that the participant has understood 
the concept of their designated group allocation. During 
the first week of the intervention, participants in the TRE 
group can change their eating window once, in case they 
are not satisfied with the originally selected window. After 
the first week no changes are allowed. To ensure similar 
contact with participants in the control group and the 
TRE group, the participants will not be contacted in case 
of non- adherence after the first week. However, if the 
participants fail to register their eating window, they will 
be contacted only to remind them to register. No other 
feedback is provided during the intervention. To account 
for variations in daily eating windows around 10 hours, 
participants in the TRE group are considered adherent 
if their eating window is less than 11 hours/day. Adher-
ence to the intervention is calculated as the number/
percentage of days during the intervention the partici-
pants’ eating window is <11 hours/day. Per protocol is 
defined as ≥80% compliance. The eating window will be 
calculated for both groups, but no compliance criterion 
is applied in the control group. Regardless of the degree 
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of adherence all participants allocated to both groups will 
be invited for test days with an emphasis on participating 
in V3 and if participants are not willing to attend a full 
test day, then they will be asked to come in for a measure-
ment of the primary outcome.
Statistical methods
Sample size determination
There is strong evidence for the clinical relevance of a 
weight reduction of 3% in people with overweight or 
obesity, with or without pre- diabetes.45 At the time when 
the RESET study was designed, no RCT had investigated 
the effects of TRE on weight loss in individuals with over-
weight or obesity at high risk of type 2 diabetes. However, 
Gill and Panda investigated the effects of a 16- week TRE 
intervention on changes in body weight in eight healthy 
overweight individuals (BMI˃25 kg/m2) with a habitual 
eating window ˃ 14 hours/day and observed a mean reduc-
tion of body weight of 3.9% (3.3 kg, 95% CI 0.9–5.6 kg); 
however, no control group was included.11 Per inclusion 
criteria individuals with a BMI of ≥25 kg/m2 are included 
in the RESET study. For the participants with a BMI of 
25 kg/m2 (with an expected mean height of 170 cm), a 
change in weight of 3% will correspond to ~2 kg. Thus, in 
order to detect a minimal clinically relevant difference in 
weight change of 3% across the allowed BMI range, the 
trial was dimensioned to detect a difference in change of 
2 kg between the TRE group and the control group. In a 
recent RCT examining the effects of 13 weeks of either 
exercise or pharmacological therapy on cardiometabolic 
health in individuals with overweight or obesity and pre- 
diabetes, the SD for within- group changes in body weight 
in the control group was 2.6 kg (Færch et al, unpublished 
data). We expect that the SD for within- group changes 
will be similar in the RESET trial, but to account for 
uncertainties we increased the SD by 20%, resulting in an 
SD of 3.1 kg. In order to detect a 2 kg (SD 3.1) difference 
in weight change with a desired statistical power of 0.8 
(two- tailed test, alpha 0.05), a total of 40 participants is 
required in each group. To allow for a 20% drop- out in 
each group, we plan to include 50 participants in each of 
the two groups.
Statistical analysis plan
Intention- to- treat analysis including all randomised 
participants will be performed after the last participant 
has participated in the last visit. Additionally, per protocol 
analysis will be performed including participants who are 
compliant during the intervention. Data will be presented 
with the use of standard descriptive statistics. Descriptive 
statistics will be shown as mean (SD) for normally distrib-
uted data and as median (Q1; Q3) for non- normally 
distributed data. Changes from baseline and differences in 
delta values between groups will be analysed using linear 
mixed- effects models with the outcome as a function of the 
group, time and group×time interaction and including 
a participant- specific random intercept. Outcomes with 
a known/expected bimodal distribution due to sex 
differences will be adjusted for sex. Adequacy of assump-
tions of normality and homogeneity of variances will be 
assessed using graphical methods and, if necessary, data 
will be log- transformed for analysis and back- transformed 
for presentation. If model assumptions are not met by 
logarithmically transformation, non- parametric statistical 
tests will be performed. P values <0.05 (two- tailed) are 
considered statistically significant. The potential impact 
of missing data on the primary outcome will be evaluated 
in a sensitivity analysis based on multiple imputation in 
which participants with missing data at follow- up will be 
pooled with the participants in the control group during 
the imputation process.
Results will be presented as estimated mean differences 
in changes with 95% CIs and p values when relevant. A 
full statistical analysis plan will be uploaded to  Clinical-
Trials. gov before the inclusion of participants is finalised.
Patient and public involvement statement
During the study, we enter into dialogue with participants 
about their experiences of the test days, examinations, 
participant information and so on with the aim to under-
stand and improve participants’ experiences in current and 
future studies of TRE.
ETHICS AND DISSEMINATION
All equipment used in the studies meet the requirement 
for patient safety. The total amount of blood taken at each 
visit is maximally 300 mL, which is less than a standard blood 
donation of 450 mL and considered safe. Participants will be 
instructed not to donate blood during the trial. There may 
be some discomfort associated with swallowing the SmartPill. 
The risk of capsule retention in individuals without known 
stenosis is only 0.75% and in such a case, a promotility drug 
is often sufficient to mobilise the capsule. Alternatively, 
endoscopy can be performed to retrieve the capsule. Body 
composition is measured using dual- energy X- ray absorp-
tiometry with a radiation dose of less than 0.01 mSv, which 
corresponds to less than 1 day of normal background radi-
ation. There is no expected discomfort or risks associated 
with the ingestion of the meals, food reward measurements 
or biometric measurements (eye tracking, galvanic skin 
response and facial expression analyses). Participants are 
covered by the Patient Compensation Association according 
to the Danish Act on the Right to Complain and Receive 
Compensation within the Health Service. The intervention is 
considered safe in individuals with overweight and obesity.46
The study has been approved by the Ethics Committee 
of the Capital Region of Denmark (H-18059188) and 
will be conducted in accordance with the Declaration of 
Helsinki. Approval of data and biobank has been obtained 
from the Danish Data Protection Agency. Consent from 
the Ethics Committee of the Capital Region of Denmark 
to all previous and future amendments to the protocol 
have and will be obtained before these are instated 
(online supplementary table 2).
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No data monitoring committee has been appointed for 
the trial due to the perceived very low risk of harm.
All study- related information will be recorded, handled 
and stored safely in a way that allows accurate reporting, 
interpretation and verification. Source data will be regis-
tered in the electronic data management system REDCap. 
For CGM measurements, source data will be registered 
in a web- based software (CareLink, Medtronic) using the 
participant’s study ID. Source data from dual- energy X- ray 
absorptiometry, biometric measurements, food prefer-
ences, Vagus, SmartPill, accelerometers and indirect calo-
rimetry are registered on the device or related hardware 
and uploaded to a secured logged drive to which only 
project staff has access. Investigators at Steno Diabetes 
Center Copenhagen will have access to the full data set. 
The sponsor/investigator will provide direct access to 
source data/documents for regulatory inspection. Access 
to the full protocol and data can be obtained from the 
principal investigator. As we expect no harm associated 
with the intervention, information on harms/side- effects 
will not be systematically recorded.
Positive and negative as well as inconclusive study results 
will be presented at conferences and published in inter-
national peer- reviewed journals in accordance with the 
CONSORT guidelines, no publication restrictions have been 
imposed. All coauthors must comply with the International 
Committee of Medical Journal Editors guidelines and no 
professional writers will be engaged in the writing process.
DISCUSSION
Implementation and maintenance of traditional strate-
gies for weight loss and early prevention of type 2 diabetes, 
that is, increased physical activity and dietary restrictions, 
are difficult for many,47–49 because it is time consuming 
and requires insights into the type and amount of foods 
eaten. From a public health perspective, there is a strong 
need for feasible lifestyle strategies to combat the current 
type 2 diabetes epidemic. TRE is a simple eating pattern 
regime that extends the daily fasting period and poten-
tially synchronises food intake with circadian rhythms 
of metabolism and may, therefore, represent a feasible 
lifestyle modification strategy. The evidence from animal 
studies and well- controlled human studies suggest that 
TRE has the potential to improve a variety of cardiomet-
abolic risk factors in metabolically vulnerable individuals 
and may be a feasible and sustainable regimen18; however, 
RCTs are lacking. Using an interdisciplinary approach, 
the present study will examine the effects of TRE on 
weight changes and explore effects on cardiometabolic 
health and behaviour, as well as on participants’ motiva-
tion and experiences with TRE.
Implicit in the trial design is that the intervention is only 
relevant and feasible if the participants can uphold the 
TRE regime without frequent contact with the research 
staff; otherwise we find it unlikely that this intervention 
will have great relevance in the public at large (who are 
likely less motivated than those opting to partake in an 
RCT). Eating is integrated into the rhythms and social 
relations in everyday life. Because TRE affects eating 
practices, it is important to get insight into participants’ 
experiences with TRE and to identify potential barriers 
and strategies for integration and maintenance of this 
regimen. Thus, the findings from the present study will 
address whether TRE is an acceptable intervention that 
can improve health outcomes in individuals at risk of 
lifestyle- related diseases. As such, it will potentially inform 
the design of future large- scale studies and feasible health 
recommendations.
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